Business Wire: September 14, 2017 – BOSTON, MA, U.S.A., and PFÄFFIKON, Switzerland – Intarcia Therapeutics, Inc., and Numab Therapeutics AG today announced the achievement of a key milestone in their ongoing development partnership—the selection of a multispecific antibody construct targeting…
